Pilot Study of RR-HNK in OCD
Recruiting · NCT06575075 · Interventional (participants receive a specific treatment) · Lead sponsor: Carolyn Rodriguez
View the official record on ClinicalTrials.gov →Interventions studied
PlaceboRR-HNK/Hydroxynorketamine
What this trial is about
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Ages 18-65
- Meet the criteria for OCD diagnosis
- Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons
- Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
- Able to provide informed consent
Exclusion criteria
- Allergy or hypersensitivity to ketamine
- Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
- Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
- Lifetime history of deep brain stimulation
Where it is running
1 location listed across 1 US state.
- Stanford University School of Medicine - Palo Alto, California, United States